GLP1R and polyneuropathy: Whilst medications like the glucagon-like-peptide 1 receptor agonists and sodium-glucose co-transporters 2 have shown significant benefit in reducing cardiovascular mortality, heart failure and chronic kidney disease associated with diabetes, there is still a substantial unmet need in the therapeutics governing DSPN and other aspects of diabetes polyneuropathy.